| 1 |
ClinicalTrials.gov (NCT05368103) A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata. U.S.National Institutes of Health.
|
| 2 |
ClinicalTrials.gov (NCT05669014) A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis. U.S.National Institutes of Health.
|
| 3 |
ClinicalTrials.gov (NCT05591222) A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus. U.S.National Institutes of Health.
|
| 4 |
ClinicalTrials.gov (NCT05540665) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy and Safety of Daxdilimab in Adult Participants With Active Proliferative Lupus Nephritis. U.S.National Institutes of Health.
|
| 5 |
ClinicalTrials.gov (NCT05430854) An Open-Label Extension Study To Evaluate The Long- Term Safety And Tolerability Of Daxdilimab (Hzn-7734) In Subjects With Systemic Lupus Erythematosus. U.S.National Institutes of Health.
|
| 6 |
Emerging drugs for the treatment of alopecia areata. Expert Opin Emerg Drugs. 2022 Dec;27(4):379-387.
|
|
|
|
|
|
|
